The award nomination is a result of a partnership which covers the development of five of OBT’s antibody and antibody drug conjugate (ADC) programmes, each of which addresses a different cancer indication via a different novel oncology target.
After proof-of-concept, OBT will be responsible for development and commercialisation in North America and Japan while Menarini will be responsible for Europe, Asia and Latin America.
Christian Rohlff, CEO of OBT, commented, “We are delighted with the nomination and hope the OBT and Menarini alliance will be considered as a benchmark for future development and manufacturing partnerships. Being nominated for the Breakthrough Alliance Award is a real testament to our innovative business framework and we hope it will inspire other companies to embrace this approach to seek new ways to develop more effective pipelines.”
This annual global award, presented at Deloitte Recap’s ALLICENSE conference, celebrates the exceptional partnering efforts of business development licensing professionals. Deloitte Recap analysts examined hundreds of biopharma license deals negotiated in 2012 and used both objective and subjective criteria, including a minimum disclosed deal size of $100 million, to identify the top five contenders for ‘deal of the year’.
Alberto Giovanni Aleotti, member of the Board of A. Menarini, commented, “Working with OBT is a fantastic opportunity, and Menarini believe that alliances like this should be embraced on a wider scale to ensure that novel and targeted therapies are brought to market efficiently, with the ultimate aim always of providing the best treatment options possible to healthcare professionals and their patients.”
Menarini and OBT are up against fellow nominees in the fields of neurology, infectious diseases/transplant, oncology and inflammation/autoimmunity. Voters must work in the biopharma or life science industry; and all votes must be received by 5pm PST / 1am GMT on 29 April 2013. To vote, please visit:
The ALLICENSE meeting brings together leading biopharma dealmakers and industry leaders in an open, collaborative forum designed to encourage debate and tackle the significant challenges facing deal making teams today. The event takes place in San Francisco, 29-30 April 2013.